KUALA LUMPUR, Oct 9 -- FibroGenesis, a fibroblast based therapeutic solutions developer has been named #2 Most Innovative Company of 2020 on Global Smart Leaders Magazine list.
A profile interview has detailed the company’s efforts to find a therapeutic cure for COVID-19.
Animal trials have shown success in reducing the scarring in the lungs for acute respiratory distress syndrome, which is the leading cause of death in COVID-19 patients.
Based on a statement, additional animal trials have shown a dramatic reduction in clotting through the therapeutic use of fibroblasts.
Additional information can also be found for FibroGenesis’s innovative approaches to curing Multiple Sclerosis, Diabetes, Cancer, Parkinson’s, Colitis and others.
“As the world leader in fibroblast cell therapy, we are continually challenging ourselves to innovate and this recognition validates our efforts to find cures for some of the toughest chronic diseases,” said FibroGenesis Chief Executive Officer, Pete O’Heeron.
More details at www.Fibro-Genesis.com
-- BERNAMA
No comments:
Post a Comment